MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Inicio・Lista de Acciones・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Cerrado

SectorSanidad

88.55 0.72

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

86.57

Máximo

89.29

Métricas clave
By Trading Economics
Ingresos	5.4M -48M
Ventas	6M 57M
Margen de beneficios	-82.974
Empleados	414
EBITDA	5.1M -43M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+53.6% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-502M 5.9B
Apertura anterior	87.83
Cierre anterior	88.55

Noticias sobre sentimiento de mercado

By Acuity

26%

74%

78 / 348 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

60 / 65.58 Soporte y Resistencia

Rhythm Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 abr 2026, 20:26 UTC

Adquisiciones, fusiones, absorciones

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 abr 2026, 18:15 UTC

Noticias de Eventos Importantes

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 abr 2026, 16:49 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 abr 2026, 16:49 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 abr 2026, 22:58 UTC

Ganancias

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 abr 2026, 21:32 UTC

Charlas de Mercado

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 abr 2026, 21:22 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 abr 2026, 21:22 UTC

Charlas de Mercado

Moody's Downgrades Belgium to A1 -- Market Talk

17 abr 2026, 20:52 UTC

Ganancias

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 abr 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

17 abr 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 abr 2026, 20:29 UTC

Ganancias

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 abr 2026, 20:11 UTC

Adquisiciones, fusiones, absorciones

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 abr 2026, 19:34 UTC

Charlas de Mercado

Ganancias

Adquisiciones, fusiones, absorciones

Global Equities Roundup: Market Talk

17 abr 2026, 19:34 UTC

Charlas de Mercado

Ganancias

Adquisiciones, fusiones, absorciones

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 abr 2026, 19:31 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 abr 2026, 19:26 UTC

Charlas de Mercado

U.S. Natural Gas Futures Edge Up -- Market Talk

17 abr 2026, 19:21 UTC

Charlas de Mercado

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 abr 2026, 19:15 UTC

Charlas de Mercado

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 abr 2026, 19:07 UTC

Charlas de Mercado

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 abr 2026, 18:57 UTC

Noticias de Eventos Importantes

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 abr 2026, 18:53 UTC

Adquisiciones, fusiones, absorciones

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 abr 2026, 18:53 UTC

Adquisiciones, fusiones, absorciones

UCB 2026 Rev Guidance Unchanged

17 abr 2026, 18:52 UTC

Adquisiciones, fusiones, absorciones

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 abr 2026, 18:52 UTC

Adquisiciones, fusiones, absorciones

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 abr 2026, 18:14 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 abr 2026, 18:00 UTC

Noticias de Eventos Importantes

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 abr 2026, 18:00 UTC

Noticias de Eventos Importantes

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 abr 2026, 17:31 UTC

Charlas de Mercado

Noticias de Eventos Importantes

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 abr 2026, 17:26 UTC

Charlas de Mercado

Ganancias

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Comparación entre iguales

Cambio de precio

Rhythm Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

53.6% repunte

Estimación a 12 Meses

Media 136.23 USD 53.6%

Máximo 158 USD

Mínimo 105 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

60 / 65.58Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentimiento

By Acuity

78 / 348 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.